免疫治疗背景下非小细胞肺癌的早期姑息治疗
化疗和早期姑息治疗
▼ 表1. 接受肿瘤治疗和姑息治疗的获益:关键研究汇总
早期姑息治疗(EPC)的作用机制
非小细胞肺癌(NSCLC)的免疫治疗
免疫疗法 vs 姑息治疗
免疫疗法和阿片类药物
结论
1. Pieniążek M, PawlakP, Radecka B. Early palliative care of non-small cell lung cancer in thecontext of immunotherapy. Oncol Lett. 2020; 20(6): 396.
2. Rinaldi S,Marcantognini G, Fiordoliva I, et. al. The negative prognostic role of opioidsin patients with NSCLC treated with immunotherapy. Presented at MASCC/ISOOAnnual Meeting on Supportive Care in Cancer, San Francisco, CA, 2019.
3. Arbour KC, MezquitaL, Long N, Rizvi H, Auclin E, Ni A, Martínez‑Bernal G, Ferrara R,Lai WV , Hendriks LEL, et al. Impact of baseline steroids on efficacy ofprogrammed cell death‑1 and programmed death‑ligand 1 blockade in patients with non–small cell lung cancer. J ClinOncol. 2018; 36(28): 2872‑2878.
4. De Giglio A,Mezquita L, Auclin E, et al. Impact of early introduction of steroid on immune‑checkpoint inhibitors (ICI) in patients with advanced non‑small cell lung cancer treated. Ann Oncol. 2019; 30 (s11): xi16.
5. Derosa L, HellmannMD, Spaziano M, et al. Negative association of antibiotics on clinical activityof immune checkpoint inhibitors in patients with advanced renal cell and non‑small cell lung cancer. Ann Oncol. 2018; 29(6): 1437‑1444.
精彩推荐:
- End -